About Source MDx

Source MDx, the leader in RNA transcript-based molecular diagnostics, focuses on whole blood to develop biomarkers that measure immune and inflammation-related responses in cancer, autoimmune, cardiovascular, infectious and other inflammatory diseases. Source MDx has developed an integrated molecular diagnostic system that measures the vital signs of the cell. This system consists of three core elements including:

• Precision Profiles™: Quantitative PCR assays optimized for precision and calibration (through matched amplification efficiencies) measuring cellular responses in a variety of pre-clinical and clinical settings.
• Normal reference ranges: Target specific gene expression ranges established from healthy human subjects or relevant clinical subpopulations allowing for comparisons to normal and treat-to-normal strategies, consistent with the accepted paradigm of medicine in the prognosis, treatment and monitoring of disease.
• Sophisticated statistical approaches: Latent class and proprietary enumeration methodologies establishing multi-gene models of clinical relevance and significance.

The company is distinguished by a decade of experience working in close collaboration with more than 30 major pharmaceutical and diagnostics firms to discover and patent biomarkers for monitoring patient health, disease status and response to therapy. Source MDx's broad-based patent portfolio with patents granted in over 20 countries, internally funded clinical studies with leading academic medical centers and practical experience gained in over 150 pre-clinical projects and clinical trials places the company in a unique position of strength in RNA transcript-based molecular diagnostics.

Collaborative and strategic partnerships with Source MDx yield substantial return on investment for pharmaceutical clients by providing high value opportunities in key areas of high impact on clinical trials including:

• Acceleration of the drug development process through improved understanding of how approved drugs and candidate compounds affect individual subjects and populations of subjects at the molecular level
• Patient stratification of healthy vs. disease and responder vs. non-responder populations
• Stratification based on patient survival assessment
• Longitudinal evaluation of safety and efficacy profiles
• Development of companion diagnostics for targeted therapies
• Rapid identification of new indications for approved drugs
• Repositioning opportunities for drugs that have failed late-stage clinical trials

Source MDx's biomarker collaborations with pharmaceutical companies such as Pfizer provide further strategic opportunities to partner with diagnostic companies in the commercialization of companion diagnostic tests for targeted therapies. Both pharmaceutical and diagnostic clients benefit from Source MDx's ability to independently generate gene expression content in defined clinical settings through an extensive collaborative network of clinical investigators and medical experts in leading academic centers. Source MDx is working with these centers to support clinical studies that will lead to the development and commercialization of FDA-approved tests for the detection, discrimination and prognosis of cancers, autoimmune, cardiovascular and infectious diseases. Finally, Source MDx's experience in generating content across multiple platform technologies further accelerates joint commercialization path opportunities for a given diagnostic on the most appropriate platform.